

Young-30  
Skang-10

Attachment 4 - Handout for H 668, March 14, 2024

Governor Brad Little

State Capitol :: Boise, Idaho 83720  
(208) 334-2100 :: gov.idaho.gov



May 1, 2023

Director Dave Jeppesen  
Department of Health and Welfare  
P.O. Box 83720  
Boise, Idaho 83720

Dear Director Jeppesen,

On April 4, 2023, I signed into law House Bill 71, The Vulnerable Child Protective Act, prohibiting children from being provided irreversible sex reassignment surgeries, puberty blockers, or hormones for the purpose of changing the appearance of a child's sex. Additionally, I have previously stated publicly my position that hardworking taxpayers should not be forced to pay for an adult's sex reassignment surgery, especially when evidence exists that such procedures are neither medically necessary nor in the best interest of the patient's mental health.

It has come to my attention that you and the Department of Health and Welfare are currently being sued for having not pre-authorized Medicaid coverage for the sex reassignment surgeries of two young adults. I further understand it has been alleged that it is unclear whether Idaho Medicaid provides coverage for such procedures.

To be clear, I oppose Idaho Medicaid using public funds to pay for irreversible sex reassignment surgeries, puberty blockers, or hormones for the purpose of changing the appearance of any child's or adult's sex. Consistent with House Bill 71, and my stated policy preference as to adults, I hereby direct you and the Department of Health and Welfare to take all appropriate steps to implement a policy consistent with state and federal law excluding the same from Medicaid coverage.

Sincerely,

Brad Little  
Governor of Idaho

EXHIBIT  
A



evidence-based

## Transgender Research: Five Things Every Parent and Policy-Maker Should Know<sup>C</sup>

published September 2022, updated November 2022

READING ONLY THE BLUE TEXT PROVIDES AN EXECUTIVE SUMMARY OF THIS DOCUMENT

The past 10 years have seen an exponential rise in the occurrence of gender confusion or gender dysphoria (also called transgender or gender non-conforming)\* among young people worldwide, especially among teenage girls. The distress of these young people is real, and the causes of this unprecedented trend are unclear, raising difficult questions about compassionate, ethical, and effective ways to respond. Experts disagree, with some recommending watchful waiting plus counseling and some asserting that cross-sex medical procedures are necessary in order to prevent suicide. The U.S. federal policy of the current administration, which endorses “early gender affirming care” for “children and adolescents” (HHS, 2022), is considered controversial by many. And the dramatic rise in use of cross-sex hormones and surgery for young people has been the focus of heated debate, causing uncertainty in patients, parents, physicians, and policy-makers as to what is best. Below is a compilation of research evidence on five key questions about these issues, shared in the hope of helping gender-confused young people receive the best care.

### 1. What does research show about the benefits and harms of cross-sex medical treatment for minors?

**Scientific evidence has not shown that cross-sex medical treatments are beneficial to children or adolescents. The research making these claims is not scientifically reliable. In fact, there is evidence of harmful impact. Consequently, a growing number of scientific agencies do not recommend such treatments. Instead, they recommend counseling and watchful waiting for gender-confused youth.**

#### Summary of Evidence

Many scientific agencies—both U.S. and international—do not recommend medical “transition” for youth because the research claiming to show positive effects from cross-sex hormones or surgery is methodologically flawed and not scientifically reliable. The limitations of these studies include lack of control groups, small sample sizes, recruitment bias, nongeneralizable study populations, short follow-up times, and high numbers lost to follow-up. However, studies finding negative outcomes from medical transition tend to be of adequate scientific quality. In other words, reliable studies have shown harmful effects. “Watchful waiting,” is the option recommended by many scientific agencies. It means deferring transgender interventions for gender-confused children or youth for an extended time during which counseling can occur and a natural desistance or persistence process can play out.

#### Highlights from Published Research (studies are listed by first author and year):

##### Sweden National Board of Health & Welfare (NBHW), 2022

- “For adolescents...the NBHW deems that the risks of puberty suppressing treatment...and gender-affirming hormonal treatment currently outweigh the possible benefits...based on...continued lack of reliable scientific evidence concerning the efficacy and the safety of both treatments.”

##### England, National Health Service (NHS)/The Cass Evidence Review, 2022

- After an evidence review, NHS determined that “gender incongruence [usually] does not persist into adolescence,” that “psychological support” and “a watchful approach” are generally recommended instead of “social transition” due to its “risks,” and that puberty blockers/cross-sex hormones will only be given to minors in a research study.
- The Cass Review found that “due to gaps in the evidence base [about hormone treatments] ...Evidence on the appropriate management of children and young people with gender incongruence and dysphoria is inconclusive.”

##### England, National Institute for Health and Care Excellence (NICE) Evidence review, 2020a

- The studies on puberty blockers “are of very low certainty [i.e., quality] using the G.R.A.D.E. rating system... As the studies all lack appropriate control [groups], any positive changes could be a regression to [the] mean.”
- The G.R.A.D.E. rating system is the most widely adopted tool for grading the quality of [research] evidence.

##### The British Medical Journal (BMJ) Evidence Review, 2019 (Henagan, C. & Jefferson, T.)

The prestigious scientific publication concluded:

- “Puberty blockers are being used in the context of profound scientific ignorance...treatments for under 18 gender dysphoric children and adolescents remain largely experimental. There are a large number of unanswered questions that include the age at start, reversibility; adverse events, long term effects on mental health, quality of life, bone mineral density, osteoporosis in later life and cognition...The current evidence base does not support informed decision making and safe practice in children.”

**Finland Board for Selection of Choices for Health Care (PALKO / COHERE Finland), 2020**

“*Medical Treatment Methods for Dysphoria Related to Gender Variance in Minors:*”

- “The first-line treatment for gender dysphoria is psychosocial support and, as necessary, psychotherapy and treatment of possible comorbid psychiatric disorders.”
- “The reliability of the existing studies with no control groups is highly uncertain, and because of this uncertainty, no decisions should be made that can permanently alter a still-maturing minor’s mental and physical development ... In light of available evidence, gender reassignment of minors is an experimental practice...no irreversible treatment should be initiated.”
- “Surgical treatments are not part of the treatment methods for dysphoria caused by gender-related conflicts in minors.” Hormonal interventions may be considered on a case-by-case basis after extensive evaluation.

**U.S. Food & Drug Administration (FDA), 2022**

- The FDA added a warning to the labeling for puberty blocking hormones (GnRH agonists): “to monitor patients taking GnRH agonists for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred or loss of vision, diplopia, pain behind the eye or pain with eye movement, tinnitus, dizziness and nausea.”
- “These hormones [puberty blockers] have FDA approval only for the treatment of precocious puberty [not gender dysphoria] in pediatric patients.” They are not approved for...halting normally timed puberty. (AbbVie, 2018).

**U.S. Medicare National Coverage Analysis (NCA) – Decision Memo, 2016**

- “Based on an extensive assessment of the clinical evidence...there is not enough high-quality evidence to determine whether gender reassignment surgery improves health outcomes...”

**Hruz, 2020**

“Deficiencies in Scientific Evidence for Medical Management of Gender Dysphoria.”

- “It is important to recognize the low quality of scientific evidence used in generating treatment recommendations ... [For example], nearly all of the recommendations made by the Endocrine Society were based upon “low” or “very low” quality evidence [according to the G.R.A.D.E. rating system]... The limitations of the published studies in...transgender medicine are many. They include a general lack of randomized controlled trial design, small sample sizes, high potential for recruitment bias, ...nongeneralizable population groups, relatively short follow-up, [and] high numbers of patients lost to follow-up... The only data that reached the level of “moderate” quality were related to adverse [i.e., harmful] medical outcomes...risks include low bone density, altered adult height, and impaired spatial memory (de Vries et al. 2011; Hough et al. 2017).”

**de Vries, 2014**

For example, this flawed study is widely cited as evidence that cross-sex hormones are beneficial to youth, yet:

- It had no control group, used a non-representative sample, and had an inadequate sample size—only 32 people for mental health outcomes, with key results based on subgroups as small as 12.
- Thus, the flawed results for 12 patients have been widely used to justify giving cross-sex hormones to children.

**Levine, 2022**

- “When evidence is assessed to be “very low certainty” [by G.R.A.D.E.], there is a high likelihood that the patients will not experience the [claimed] effects of the proposed interventions (Balshem et al., 2011).”
- “In the context of providing puberty blockers and cross-sex hormones, the [G.R.A.D.E.] designation of ‘very low certainty’ signals that the body of evidence asserting the benefits of these interventions is highly unreliable.”
- “In contrast, several negative effects are quite certain. For example, puberty blockade followed by cross-sex hormones leads to infertility and sterility (Laidlaw, Van Meter, Hruz, Van Mol, & Malone, 2019). Surgeries to remove breasts or sex organs are irreversible. Other health risks includ[e] risks to bone and cardiovascular health.”

**Alzahrani, 2019; Nota, 2019; Getahun, 2018**

- At least three studies have found significantly elevated rates of acute cardiovascular events (such as heart attacks and strokes) in transgender adults who have received cross-sex hormone treatment.

**Turner, 2022**

An investigation of England’s Gender Identity Development Service (GIDS) for *The Times Magazine* found:

- “A barely pubescent child prescribed [puberty] blockers who goes on to take cross-sex hormones—as almost every patient does—will be infertile and unable to orgasm.”
- Transgender lobby groups influenced GIDS in favor of medical transition of children, despite scientific evidence.
- Britain’s National Health Service is closing the GIDS clinic due to concerns about patient safety (Glebova, 2022).

### Cantor, 2019

- “Although almost all clinics and professional associations in the world use what’s called the watchful waiting approach to helping transgender and gender diverse (GD) children, the AAP [American Academy of Pediatrics] statement rejected that consensus, endorsing only gender affirmation. That is, where the consensus is to delay any transitions [until] after the onset of puberty, AAP instead rejected waiting before transition... As I read the works on which they based their policy, I was... alarmed: These documents simply did not say what AAP claimed they did. In fact, the references that AAP cited as the basis of their policy instead outright contradicted that policy, repeatedly endorsing watchful waiting.”

### The Society for Evidence-Based Gender Medicine, 2022

- A review of the cited scientific support for the U.S. Department of Health & Human Services recent policy statement that “For transgender and nonbinary children and adolescents, early gender affirming care is crucial to overall health and well-being” (HHS Office of Population Affairs, 2022) found misstatements of study findings, use of one flawed study as evidence for major claims, misrepresentation of treatment “reversibility,” lack of evidence for the claims made, a failure to discuss the well-documented risks, and no presentation of alternatives.

## 2. What does research on medical gender transition tell us about preventing suicide in trans youth?

**Research does not show that medical gender transition is necessary to prevent suicide. In fact, there is evidence that medical transition procedures may increase suicide risk in gender-confused teens.**

### Summary of Evidence

The “transition or suicide” claim—that parents must choose between a “live trans son or a dead daughter” (or vice-versa)—is not supported by scientific evidence. Widely cited studies claiming that suicidality in gender-confused youth is reduced by cross-sex hormonal and surgical interventions have been found to have significant methodological flaws and therefore should not be relied on. Scientifically sound studies have found either no reduction or an increase in transgender suicidality after youth have received cross-sex medical procedures.

### Highlights from Published Research:

#### Dhejne, 2011

A Swedish study recognized as a landmark 30-year longitudinal study of life after transgender surgery found that...

- Ten years after sex reassignment surgery, the transgender patients were 19 times more likely to die from suicide than the typical Swedish population, after accounting for differences in individual mental illness before surgery.
- Those transitioning “male-to-female are at higher risk for suicide attempts after sex reassignment.”
- The study authors concluded: “...surgery and hormonal therapy...is apparently not sufficient to remedy the high rates of [mental illness] and mortality found among transsexual persons... Our findings suggest that sex reassignment, although alleviating gender dysphoria, may not suffice as treatment for transsexualism...”
- A U.S. Medicare National Coverage Analysis (NCA) Decision Memo (2016), which reviewed this Dhejne study, stated: “we cannot exclude therapeutic interventions [i.e., transgender surgery] *as a cause* of the observed excess [mental illness] and mortality” (p. 62, emphasis added).

#### Heylens, 2014

- Although the study reported a reduction in patients’ psychological distress, there was no reduction in suicide attempts at any step in the process of cross-sex medical intervention.

#### Bauer, 2015

- Although there was a decrease in “suicidal thoughts” after cross-sex hormonal intervention, among those who did have suicidal thoughts, being in the process of cross-sex medical treatment was associated with a three-fold increase in actual suicide attempts.

#### Adams, 2017

A meta-analysis of 42 studies of suicidality in transgender adults reported...

- Suicidal thoughts appeared to increase after medical transition and suicide attempts did not appear to decrease.

#### Branstrom, 2020b

A 10-year study on the impact of cross-sex hormones and/or surgery on patients’ mental health, found...

- “...the results demonstrated no [positive effects] of surgery in relation to subsequent mood or anxiety disorder-related health care visits or prescriptions or hospitalizations following suicide attempts.”

### Wiepjes, 2020

- “An important finding was that the incidence for observed suicide deaths was almost equally distributed over the different stages of treatment” (i.e., the suicide rate was roughly the same before and after cross-sex surgery).

### Turban, 2020

A weak study widely cited as showing that puberty blockers reduce suicidality, actually obscured contradictory findings:

- The study employed the inferior correlational research design which is not able to test causality.
- The study Abstract (or summary) reported that puberty blockers had reduced Suicidal Thoughts in adolescents, but the author failed to include in the Abstract that there was no reduction in the more serious measures of suicidality: Suicide Attempts, Lifetime Suicide Attempts, and Suicide Attempts Resulting in Hospitalization—all key findings.
- The study results suggest that recent suicide attempts may have increased after puberty blockers, although not significant due to small numbers. And 75% of those who received puberty blockers still had suicidal thoughts.

### Carmichael, 2021

- A recent study, patterned after an early study in the Netherlands that said puberty blockers improved mental health in transgender youth (deVries, 2011), found puberty blockers had no positive effect on mental health or suicidality.

### Turban, 2022

A recent study, often named as evidence that cross-sex hormones during adolescence reduce suicidality in adults, obscures contradictory findings and seems to downplay evidence suggesting increased suicidality for 16-17-year-old patients:

- The study had only a correlational research design, used a non-representative sample, lacked adequate controls for pre-existing mental health, and combined the effects of two very different hormones (testosterone and estrogen).
- The study Abstract reported a reduction in Suicidal Thoughts for those starting cross-sex hormones by age 17 as evidence of “favorable outcomes” from this treatment. But there was no reduction in the more serious measures of suicidality—Suicidal Thoughts with Plan, Suicide Attempt, or Suicide Attempt requiring Hospitalization—related to the use of cross-sex hormones at any age. As in his previous study (Turban, 2020), the author failed to include these contradictory and more important findings in the Abstract, where key results/non-results should be reported.
- 16- and 17-year-olds who received hormones were more than twice as likely to report a “past-year suicide attempt requiring inpatient hospitalization” (aOR=2.2, p<.01). But by setting the cut-off for statistical significance much higher than is standard in empirical research (i.e., at p<.001 instead of p<.05—a debatable Bonferroni correction) the study avoided reporting this as an increase in suicidality related to hormone therapy in adolescence.

### Biggs, 2022a

A second analysis of the same data used in Turban, 2022 (above entry), found...

- Use of cross-sex hormones significantly increased suicidality (nearly two-fold) for biological males receiving estrogen—increases in Suicidal Thoughts with Plan, Suicide Attempt, and Suicide Attempt Requiring Hospitalization—when the effects were analyzed separately for biological males compared to females.
- Receiving puberty blockers in adolescence did not reduce any measure of suicidality.

### Tordoff, 2022; Reddit 2022

This flawed study is purported to show that cross-sex hormones reduced depression and suicidality rates in 57 adolescents:

- However, the study reported no significant declines in these rates from baseline to the 12-month follow-up; they remained high, at 56% depressed and 37% with suicidal thoughts, 12 months after the start of hormonal treatment.
- The hormonal “reductions” were claimed because the rates did not *increase* as they did for the group not receiving hormones, whose rates increased greatly by the 12-month follow-up. But unlike the hormone group, this group had 82% drop out of the study, reducing it to only 7 youth and invalidating its use as a legitimate comparison group.
- These data, in the study Supplement, do not show that cross-sex hormones improved mental health in trans youth.

### Biggs, 2022b

Longitudinal analysis of patient records from the world’s largest clinic for transgender youth:

- There was no difference in the suicide rate for those who had not yet received treatment and those who had received treatment (puberty blockers and/or cross-sex hormones).
- “It is irresponsible to exaggerate the prevalence of suicide... Data from the world’s largest clinic for transgender youth, accumulated over an 11-year period, [found that] ... The proportion of individual patients who died by suicide was 0.03% [or 3 out of 10,000], which is orders of magnitude smaller than the proportion of transgender adolescents who report attempting suicide when surveyed.”
- The finding that [actual] deaths were so rare is helpful information for transgender youth and their families.

### Levine, 2022

- “The “transition or suicide” narrative falsely implies that transition will prevent suicides... [Yet,] neither hormones nor surgeries have been shown to reduce suicidality in the long-term... [Thus,] the “transition or die” narrative, whereby parents are told that their only choice is between a “live trans daughter or a dead son” (or vice-versa), is both factually inaccurate and ethically wrong.”

### **3. Is gender dysphoria in children a permanent condition, and one that requires medical treatment?**

**Research shows gender dysphoria in children usually goes away on its own by young adulthood, if “transition” is not encouraged. This avoids the harmful effects of cross-sex medical interventions.**

#### **Summary of Evidence**

There is strong evidence showing that the vast majority of children (averaging about 85%) who experience gender dysphoria will resolve their gender identity confusion and accept their biological sex by the time they reach young adulthood, that is, if they are not subjected to “social transition” or cross-sex medical intervention. But for those who are the subject of early transition efforts, the large majority will most likely persist in a “trans” identity. (“Social transition” refers to cross-sex dressing and social reinforcement of a transgender identity for children by adults.)

#### **Highlights from Published Research:**

##### **Steensma, 2015**

- “In long-term follow-up [into young adulthood], the childhood sample showed 66.7% desistence.” That is, by young adulthood, two-thirds of those with childhood gender dysphoria did not identify as transgender. (As quoted in Cantor, 2020.)

##### **Ristori & Steensma, 2016**

- A review of 10 studies measuring the persistence of childhood gender dysphoria found that, by the follow-up time in adolescence or young adulthood, 2% to 39% of cases had persisted in gender dysphoria or transgender identity, resulting in an average of 85% who identified with their biological sex at that point.

##### **Zucker, 2018**

- Results of four studies: “Among children meeting the diagnostic criteria for “Gender Dysphoria” ...67% were no longer gender-dysphoric as adults; the rate of natural resolution for gender dysphoria was 93% for children whose gender dysphoria was significant but [did not reach a medical] diagnosis” (as quoted by Levine, 2022).

##### **Singh, 2021**

- 88% of boys with childhood gender dysphoria did not identify as transgender by young adulthood.

##### **Steensma, 2013**

- Young children who experience early social “transitioning” (i.e., cross-sex dressing and identification and “affirmation” of a transgender role by adults) are more likely to persist in a transgender identity.

##### **de Vries, 2011; van der Loos, 2022**

- Study results support the view that puberty blockers disrupt the natural desistence process, funneling kids into an irreversible path of cross-sex hormones (whose negative side-effects include infertility, see Cheng, et al., 2019).

### **4. Can young people be influenced to identify as transgender, or is it all biologically determined?**

**Scientific evidence indicates that the causes of gender dysphoria are complex. Social and cultural factors can have a significant influence on whether a young person will identify as transgender.**

#### **Summary of Evidence**

Recent unprecedented increases in transgender identity worldwide suggest that non-biological influences are a major factor. Genetic studies show gender identity development is a complex process with bio-psycho-social components. This means children and young people are susceptible to social, educational, and cultural influences.

#### **Highlights from Published Research:**

##### **Heylans, 2012**

A systematic review of research on identical twins and gender dysphoria...

- Concluded that the 39% concordance rate for transgender identity in identical twins (i.e., where both were transgender) was “consistent with a genetic influence...although shared and nonshared environmental factors cannot be ruled out... [Gender identity development] is a complex process of biopsychosocial components.”
- While this suggests “a role for genetic factors in the development of [gender dysphoria],” it also indicates a significant role played by social and environmental factors for many individuals.
- The study found the influence of social factors was higher for biological females than males.

### Jones, 2021

- A recent U.S. Gallup Poll found that the percent of Generation Z (born 1997 – 2002) who identify as transgender has increased by 900% over the percent of Generation X (born 1965 – 1980), who say they are transgender.

### The Economist, 2020; Turner, 2022

- In Great Britain, between 2010 and 2020, the number of teenage girls referred for gender dysphoria (GD) to the largest pediatric gender clinic in the world, increased by about 5000%, while the rates for girls under age 12 saw only small increases. Rates for teenage boys also increased dramatically, although much less than for girls, with similarly small increases for boys under 12. In Sweden, GD in teen girls has risen 1500% in a similar time span.
- This pattern suggests that the exponential increase in GD for teen girls (which did not occur for preteens) may be due to social influence, i.e., transgender identity promotion, rather than merely an increase in public acceptance.

### Zucker, 2019; Littman, 2018 & 2019

- There has been a recent dramatic reversal in the male-to-female sex ratio of transgender youth, with biological females now far out-numbering males (the previous consistent ratio of about 2:1 has now changed to a ratio ranging from 1:2 to 1:7), coupled with a corresponding recent dramatic “increase in the number of adolescents referred to specialized gender identity clinics/programs [which] has become an international phenomenon, observed all across North America, Europe, Scandinavia, and elsewhere” (Zucker, 2019).
- These changes are considered by some experts to be an important new clinical phenomenon that needs to be studied and better understood, especially the role of social influences (Zucker 2019, Littman, 2018/9).

### Downey, 2022; Mason, 2022

- A popular researcher advocating for the use of puberty blockers in children—who has been funded by an agency that receives financial support from the makers of puberty blockers—claims to have shown that social influence is not a cause of the recent worldwide explosion in rates of gender dysphoria. However, his research has been criticized for its use of an invalid survey measure and for using only U.S. data, as well as for a conflict of interest.

## **5. What does research tell us about teaching sex education and gender ideology to young children?**

**There is no scientific evidence showing that young children benefit from being taught in school about sexuality, transgender identity, or homosexuality, or showing that such teaching does not do harm.**

### **Summary of Evidence**

Studies to date have not produced sound scientific evidence to back up the claim that teaching sex education to young children in early elementary school, including content about transgender ideology and homosexuality, is beneficial to them or reduces rates of child sex abuse. There is also no evidence that it is not harmful. And research has not shown reliable evidence that sex education classes which teach these topics to older youth produce any psychosocial benefit.

### **Highlights from Published Research**

#### **Goldfarb & Lieberman, 2021; critique of Goldfarb & Lieberman by Ericksen & Weed, 2022**

Contrary to its claims, a wide-ranging review of research on school-based sex education in the U.S. and internationally...

- Showed no credible scientific evidence that sexuality education is beneficial to children in early elementary school or that it reduces child sex abuse. Child sex abuse programs have shown some benefits, but not actual reductions.
- Found no scientifically credible research demonstrating that teaching young children about transgender ideology or homosexuality in school is beneficial to them or has any other positive impact. No scientifically sound studies were found on this, or that tested possible negative impacts. Thus, it is unknown whether these programs do harm.
- Studies cited as showing benefits from teaching transgenderism and homosexuality in sex education classes for older grades were not scientifically capable of measuring this impact and also showed conflicting results.

## **SUMMARY of FINDINGS**

***1) Research evidence does not support medical intervention for gender-confused minors. 2) Medical transition procedures have not been shown to reduce youth suicides. 3) Childhood gender dysphoria usually dissipates on its own by adulthood. 4) The dramatic increase in gender dysphoria in the past decade is likely being driven by social influence. 5) Sex education for early elementary school children, including content about transgender ideology, has not been shown by scientific research to be beneficial.***

## \*GLOSSARY of TERMS

For the purposes of this paper, we use the following definitions:

**Gender Dysphoria:** A diagnostic term for a person experiencing profound discomfort with their biological/natal sex.

**Gender Confusion:** A nonclinical term that refers to a person's feeling of not identifying with his or her biological sex.

**Transgender:** This refers to a person whose declared gender identity does not match that person's biological sex at birth.

**Gender Non-Conforming:** This term refers to a person whose behavior or appearance does not conform to prevailing cultural and social expectations about what is appropriate for their biological sex at birth.

## REFERENCES

- AbbVie. 2018. Lupron Depot (Leuprolide acetate) Product Monograph. Chicago: AbbVie Corporation.
- Adams, N., M. Hitomi, and C. Moody. 2017. "Varied Reports of Adult Transgender Suicidality: Synthesizing and Describing the Peer-Reviewed and Gray Literature." *Transgender Health* 2:60–75.
- Alzahrani, T., Nguyen, T., Ryan, A., Dwairy, A., McCaffrey, J., Yunus, R., Forgione, J., Krepp, J., Nagy, C., Mazhari, R., & Reiner, J. (2019). Cardiovascular disease risk factors and myocardial infarction in the transgender population. *Circulation: Cardiovascular Quality and Outcomes*, 12(4). doi:10.1161/CIRCOUTCOMES.119.005597
- Balshem, H., Helfand, M., Schunemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011). GRADE guidelines: 3. Rating the quality of evidence. *Journal of Clinical Epidemiology*, 64(4), 401–406. doi:10.1016/j.jclinepi.2010.07.015
- Bauer GR, Scheim AI, Pyne J, Travers R, Hammond R. (2015). Intervenable factors associated with suicide risk in transgender persons: a respondent driven sampling study in Ontario, Canada. *BMC Public Health*, 15:525.
- Biggs M. (2022a). "Comment on Turban et al. 2022: Estrogen Is Associated with Greater Suicidality Among Transgender [Fe]Males, and Puberty Suppression Is Not Associated with Better Mental Health Outcomes for Either Sex." figshare. journal contribution, 2022. <https://doi.org/10.6084/m9.figshare.19018868.v1>
- Biggs M. (2022b). Suicide by clinic-referred transgender adolescents in the United Kingdom. *Archives of Sexual Behavior*. <https://doi.org/10.1007/s10508-022-02287-7>
- Branstrom, R., & Pachankis, J. E. (2020b). Correction to Branstrom and Pachankis. (2020). *American Journal of Psychiatry*, 177(8), 734–734. doi:10.1176/appi.ajp.2020.1778correction
- Burke, S. M., P. T. Cohen-Kettenis, D. J. Veltman, D. T. Klink, and J. Bakker. 2014. Hypothalamic Response to the Chemo-Signal Androstadienone in Gender Dysphoric Children and Adolescents. *Front Endocrinol (Lausanne)* 5:60. doi: 10.3389/fendo.2014.00060.
- Cantor, J. M. (2019). Transgender and gender diverse children and adolescents: Fact-checking of AAP Policy. *Journal of Sex & Marital Therapy*, 46(4), 307–313. doi:10.1080/0092623X.2019.1698481
- Carmichael P, Butler G, Masic U, Cole TJ, De Stavola BL, Davidson S, et al. (2021) Short term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. *PLoS ONE* 16(2): e0243894
- Cheng PJ, Pastuszak AW, Myers JB, Goodwin IA, Hotaling JM. (2019). Fertility concerns of the transgender patient. *Transl Androl Urol*;8(3):209-218.
- Delemarre-van de Waal, H.A. and Cohen-Kettenis, P.T. (2006) Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects, *European Journal of Endocrinology*, 155:S131–S137
- de Vries, A. L., T. D. Steensma, T. A. Doreleijers, and P. T. Cohen-Kettenis. 2011. "Puberty Suppression in Adolescents with Gender Identity Disorder: A Prospective Follow-Up Study." *Journal of Sexual Medicine* 8:2276–83. doi: 10.1111/j.1743-6109.2010.01943.x; de Vries AL, McGuire JK, Steensma TD, Wagenaar EC, Doreleijers TA, CohenKettenis PT. (2014). Young adult psychological outcome after puberty suppression and gender reassignment. *Pediatrics*;134(4):696–704.
- Dhejne C, Lichtenstein P, Boman M, Johansson ALV, Langstrom N, et al. (2011) Long-Term Follow-Up of Transsexual Persons Undergoing Sex Reassignment Surgery: Cohort Study in Sweden. *PLoS ONE* 6(2): e16885.
- Downey C. (2022). 'Advocate Rather Than a Scientist': The Compromised Research of Child Gender-Transition Doctor Jack Turban. *National Review Online*, August 16, 2022. Available at: [https://www.nationalreview.com/news/advocate-rather-than-a-scientist-the-compromised-research-of-child-gender-transition-doctor-jack-turban/?utm\\_source=onesignal&utm\\_medium=push&utm\\_campaign=article](https://www.nationalreview.com/news/advocate-rather-than-a-scientist-the-compromised-research-of-child-gender-transition-doctor-jack-turban/?utm_source=onesignal&utm_medium=push&utm_campaign=article)
- Drummond, K. D., S. J. Bradley, M. Peterson-Badali, and K. J. Zucker. 2008. "A Follow-Up Study of Girls with Gender Identity Disorder." *Developmental Psychology* 44:34–45. doi: 10.1037/0012-1649.44.1.34.
- England, National Health Service (2022). Interim service specification: Specialist service for children and young people with gender dysphoria (phase 1 providers) 20 October 2022. Available at: [https://www.engage.england.nhs.uk/specialised-commissioning/gender-dysphoria-services/user\\_uploads/b1937-ii-specialist-service-for-children-and-young-people-with-gender-dysphoria-1.pdf](https://www.engage.england.nhs.uk/specialised-commissioning/gender-dysphoria-services/user_uploads/b1937-ii-specialist-service-for-children-and-young-people-with-gender-dysphoria-1.pdf); The Cass Review. (2022). Independent review of gender identity services for children and young people: Interim report. February 2022. Available at: <https://cass.independent-review.uk/publications/interim-report/>
- England, National Institute for Health and Care Excellence (NICE). (2022a). Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria. Available at: <https://arms.nice.org.uk/resources/hub/1070905/attachment>



- Ericksen IH and Weed SE. (2022). "Three Decades of Research:" A New Sex Ed Agenda Wrapped in the Veneer of Science. Salt Lake City: *The Institute for Research & Evaluation*. Available at: [https://institute-research.com/pdf/Rebuttal\\_to\\_Goldfarb\\_and\\_Lieberman\\_2021\\_%28IRE%209-26-22%29.pdf](https://institute-research.com/pdf/Rebuttal_to_Goldfarb_and_Lieberman_2021_%28IRE%209-26-22%29.pdf)
- Finland Board for Selection of Choices for Health Care (PALKO / COHERE Finland). (2020). Medical Treatment Methods for Dysphoria Related to Gender Variance in Minors. Official English Translation, May 18, 2022.
- Getahun, D., Nash, R., Flanders, W. D., Baird, T. C., Becerra-Culqui, T. A., Cromwell, L., Hunkeler, E., Lash, T. L., Millman, A., Quinn, V. P., Robinson, B., Roblin, D., Silverberg, M. J., Safer, J., Slovis, J., Tangpricha, V., & Goodman, M. (2018). Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons. *Annals of Internal Medicine*, 169(4), 205–213.
- Glebova, D. (2022). English Gender-Identity Center to Close after Report Finds It Not 'Safe.' *National Review Online*. Available at: <https://www.nationalreview.com/news/english-gender-identity-center-to-close-after-report-finds-it-not-safe/>
- Goldfarb E, Lieberman L. (2021). Three Decades of Research: The Case for Comprehensive Sex Education. *J Adolesc Health*, 68(1):13-27. doi: 10.1016/j.jadohealth.2020.07.036
- GRADE (Grading of Recommendations, Assessment, Development and Evaluations). See: <https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/>
- Henagan, C. & Jefferson, T. (2019). Gender-affirming hormone in children and adolescents. *British Medical Journal (BMJ) Evidence Review*. Available at: <https://blogs.bmj.com/bmjebmspotlight/2019/02/25/gender-affirming-hormone-in-children-and-adolescents-evidence-review/>
- Heylens, G., De Cuypere, K. J. Zucker, C. Schelfaut, E. Elaut, H. Vanden Bossche, E. De Baere, et al. (2012). Gender Identity Disorder in Twins: A Review of the Case Report Literature. *Journal of Sexual Medicine* 9:751–57.
- Heylens G, Verroken C, De Cock S, T'Sjoen G, De Cuypere G. (2014). Effects of different steps in gender reassignment therapy on psychopathology: A prospective study of persons with a gender identity disorder. *J Sex Med*; 11: 119-26.
- HHS Office of Population Affairs. (2022). Gender-Affirming Care and Young People. <https://opa.hhs.gov/sites/default/files/2022-03/gender-affirming-care-young-people-march-2022.pdf>
- Hough, D., M. Bellingham, I. R. H. Haraldsen, M. McLaughlin, M. Rennie, J. E. Robinson, A. K. Solbakk, and N. P. Evans. 2017. "Spatial Memory Is Impaired by Peripubertal GnRH Agonist Treatment and Testosterone Replacement in Sheep." *Psychoneuroendocrinology* 75:173–82. doi: 10.1016/j.psyneuen.2016.10.016.
- Hruz, P.W. (2020). Deficiencies in Scientific Evidence for Medical Management of Gender Dysphoria. *The Linacre Quarterly*, 87(1) 34-42. DOI: 10.1177/0024363919873762
- Ismail, Fatima Yousif, Ali Fatemi, and Michael V. Johnston. (2017). "Cerebral Plasticity: Windows of Opportunity in the Developing Brain." *European Journal of Paediatric Neurology* 21:23–48. doi: 10.1016/j.ejpn.2016.07.007.
- Jones, JM. (2021). LGBT Identification Rises to 5.6% in Latest U.S. Estimate. *Gallup Poll Social Series*. February 24, 2021. Available at: <https://news.gallup.com/poll/329708/lgbt-identification-rises-latest-estimate.aspx>
- Laidlaw, M. K., Van Meter, Q. L., Hruz, P. W., Van Mol, A., & Malone, W. J. (2019). Letter to the Editor. "Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society Clinical Practice Guideline." *The Journal of Clinical Endocrinology & Metabolism*, 104(3), 686–687. doi:10.1210/jc.2018-01925
- Levine SB, Abbruzzese E, Mason JW. (2022): Reconsidering Informed Consent for Trans-Identified Children, Adolescents, and Young Adults, *Journal of Sex & Marital Therapy*, DOI: 10.1080/0092623X.2022.204622
- Littman L. (2018). Parent reports of adolescents and young adults perceived to show signs of a rapid onset of gender dysphoria. *PLoS ONE*. 13(8): e0202330. <https://doi.org/10.1371/journal.pone.0202330> PMID: 30114286
- Littman L (2019) Correction: Parent reports of adolescents and young adults perceived to show signs of a rapid onset of gender dysphoria. *PLoS ONE* 14(3): e0214157. <https://doi.org/10.1371/journal.pone.0214157>
- Luders, E., F. J. Sanchez, C. Gaser, A. W. Toga, K. L. Narr, L. S. Hamilton, and E. Vilain. (2009). "Regional Gray Matter Variation in Male-to-Female Transsexualism." *Neuroimage* 46:904–7. doi: 10.1016/j.neuroimage.2009.03.048.
- Mason J. and Sapir L. (2022). The American Academy of Pediatrics' Dubious Transgender Science. *The Wall Street Journal*, August 17, 2022. Available at: <https://www.wsj.com/articles/the-american-academy-of-pediatrics-dubious-transgender-science-jack-turban-research-social-contagion-gender-dysphoria-puberty-blockers-uk-11660732791>
- Nota, N. M., Wiepjes, C. M., de Blok, C. J. M., Gooren, L. J. G., Kreukels, B. P. C., & den Heijer, M. (2019). Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy: Results From a Large Cohort Study. *Circulation*, 139(11), 1461–1462. <https://doi.org/10.1161/CIRCULATIONAHA.118.038584>
- Reddit. (2022). "Transgender and nonbinary youth who received gender affirming medical care experienced greatly reduced rates of suicidality and depression over the course of 12 months." This archived post, deleted in March, 2022, shows the claims initially being made about the Tordoff, et al., 2022, study. Available at: [https://www.reddit.com/r/science/comments/t5kaiy/transgender\\_and\\_nonbinary\\_youth\\_who\\_received/](https://www.reddit.com/r/science/comments/t5kaiy/transgender_and_nonbinary_youth_who_received/)
- Ristori J and Steensma TD. (2016). Gender dysphoria in childhood. *International Review of Psychiatry* 28:13-20. DOI: <https://doi.org/10.3109/09540261.2015.1115754>
- Schagen SEE, Wouters FM, Cohen-Kettenis PT, Gooren LJ, Hannema SE. (2020). Bone Development in Transgender Adolescents Treated With GnRH Analogues and Subsequent Gender-Affirming Hormones. *The Journal of Clinical Endocrinology & Metabolism*, Volume 105: e4252–e4263
- Singh, D., Bradley, S. J., & Zucker, K. J. (2021). A follow-up study of boys with gender identity disorder. *Frontiers in Psychiatry*, 12. doi:10.3389/fpsy.2021.632784

Society for Evidence-Based Gender Medicine. (2021). *New Systematic Reviews of Puberty Blockers and Cross-Sex Hormones Published by NICE: Weighing potential benefits against profound long-term uncertainties*. Available at: [https://segm.org/NICE\\_gender\\_medicine\\_systematic\\_review\\_finds\\_poor\\_quality\\_evidence](https://segm.org/NICE_gender_medicine_systematic_review_finds_poor_quality_evidence)

Society for Evidence-Based Gender Medicine. (2022). Early Social Gender Transition in Children is Associated with High Rates of Transgender Identity in Early Adolescence. May 6, 2022. Available at: <https://segm.org/early-social-gender-transition-persistence>

Society for Evidence-Based Gender Medicine. (2022). Fact-checking the HHS. See: <https://segm.org/fact-checking-gender-affirming-care-and-young-people-HHS>

Steensma, T. D., & Cohen-Kettenis, P. T. (2015). More than two developmental pathways in children with gender dysphoria? *Journal of the American Academy of Child and Adolescent Psychiatry*, 52, 147–148. doi:10.1016/j.jaac.2014.10.016

Steensma, T.D., McGuire, J.K., Kreukels, B.P., Beekman, A.J., & Cohen-Kettenis, P.T. (2013). Factors associated with desistance and persistence of childhood gender dysphoria: a quantitative follow-up study. *Journal of the American Academy of Child and Adolescent Psychiatry*, 52, 582–590.

Swedish National Board of Health & Welfare. (2022). *Cure of Children and Adolescents with Gender Dysphoria: Summary*.

The Economist Group Limited. (2020). An English ruling on transgender teens could have global repercussions. *The Economist*, International, December 12, 2020. Available at: <https://www.economist.com/international/2020/12/12/an-english-ruling-on-transgender-teens-could-have-global-repercussions>

Tordoff, D.M., Wanta, J.W., Collin, A., Stepney, C., Inwards-Breland, D.J., and Ahrens, K. (2022). Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care. *Pediatrics. JAMA Network Open*. 2022;5(2):e220978. doi:10.1001/jamanetworkopen.2022.0978

Turban JL, King D, Carswell JM, Keuroghlian AS. (2020). "Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation," *Pediatrics*, Vol. 145, No. 2, p. e20191725,

Turban JL, King D, Kobe J, Reisner SL, Keuroghlian, (2022) "Access to Gender-Affirming Hormones During Adolescence and Mental Health Outcomes Among Transgender Adults," *PLOS ONE*, Vol. 17, No. 1 (January 12, 2022), p. e0261039, <https://doi.org/10.1371/journal.pone.0261039>

Turner, J. (2022). Special Report: What went wrong at the Tavistock clinic for transgender teens? *The Times Magazine*. June 17, 2022. Available at: <https://segm.org/GIDS-puberty-blockers-minors-the-times-special-report>

U.S. Food & Drug Administration. (2022). *Risk of pseudotumor cerebri added to labeling for gonadotropin-releasing hormone agonists*. Available at: [https://aap2.silverchair-cdn.com/aap2/content\\_public/autogen-pdf/cms/20636/20636.pdf?Expires=2147483647&Signature=bhuLz12pTNS27GJq54IBzVMvmyjPxTwiMxeF9P4qUBbCffnXEUEmNpI2rHmXvh7VbZiTsBduxGL5q4ZvLpm-Fr7VOVtxM-n9hKHXTurpexaFK5dcE2YWyfo4-ALsTD3GMP7d2oLgMr0vFgjPhXId6DPFJLVwncClprhKlv8zWjTZLcQYtbOEy4kTOOKRsvM-S-Snlyd7X~nT295Lnr4yO~bxrKkSLY2uZihitrc3jnLv0ruS1gMZ0XIFYKRsbDFlvNn3mL68psGgN9LLN2SP9p31agUAz4Zcj00FPTmbnCx2m2nxpsbfxXypvUGin7qkWuHQA7ajVmu5redYA\\_\\_&Key-Pair-Id=APKAIESG5CRDK6RD3PGA](https://aap2.silverchair-cdn.com/aap2/content_public/autogen-pdf/cms/20636/20636.pdf?Expires=2147483647&Signature=bhuLz12pTNS27GJq54IBzVMvmyjPxTwiMxeF9P4qUBbCffnXEUEmNpI2rHmXvh7VbZiTsBduxGL5q4ZvLpm-Fr7VOVtxM-n9hKHXTurpexaFK5dcE2YWyfo4-ALsTD3GMP7d2oLgMr0vFgjPhXId6DPFJLVwncClprhKlv8zWjTZLcQYtbOEy4kTOOKRsvM-S-Snlyd7X~nT295Lnr4yO~bxrKkSLY2uZihitrc3jnLv0ruS1gMZ0XIFYKRsbDFlvNn3mL68psGgN9LLN2SP9p31agUAz4Zcj00FPTmbnCx2m2nxpsbfxXypvUGin7qkWuHQA7ajVmu5redYA__&Key-Pair-Id=APKAIESG5CRDK6RD3PGA)

U.S. Medicare National Coverage Analysis (NCA) Decision Memo (2016). *Gender dysphoria and gender reassignment surgery* (CAG-00446N). Centers for Medicare & Medicaid Services, Available at: <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=282&bc=ACAAAAAAQAAA&>

van der Loos M, Hannema S, Klink D, Heijer M, Wiepjes C. (2022). Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands. *The Lancet Child & Adolescent Health*. October 20, 2022. DOI:10.1016/S2352-4642(22)00254-1

Wiepjes, C. M., den Heijer, M., Bremmer, M. A., Nota, N. M., Blok, C. J. M., Coumou, B. J. G., & Steensma, T. D. (2020). Trends in suicide death risk in transgender people: Results from the Amsterdam Cohort of Gender Dysphoria Study (1972–2017). *Acta Psychiatrica Scandinavica*, 141(6), 486–491. doi:10.1111/acps.13164

Zucker, K. J. (2018). The myth of persistence: Response to "A critical commentary on follow-up studies and 'desistance' theories about transgender and gender non-conforming children" by Temple Newhook et al. (2018). *International Journal of Transgenderism*, 19(2), 231–245. doi:10.1080/15532739.2018.1468293

Zucker KJ. (2019). Adolescents with Gender Dysphoria: Reflections on Some Contemporary Clinical and Research Issues. *Archives of Sexual Behavior* 48:1983–1992. Available at: [www.segm.org](http://www.segm.org) or [https://link.springer.com/epdf/10.1007/s10508-019-01518-8?sharing\\_token=ibyVqzajw\\_5oCp2gORwKfe4RwlQNchNByi7wbcMAy6LNL5nWifAZ0Tz7RsvNs8G4Hfdu\\_I29pZ5Oyo0IZT\\_TGHtswOdNyZebFztiQIyv4jzVsT\\_HYabCYqpf-0VT5VSURUjxJEMdZPUO18mhGz9WBtEmM9gwKQxxcO4E\\_xl%3D](https://link.springer.com/epdf/10.1007/s10508-019-01518-8?sharing_token=ibyVqzajw_5oCp2gORwKfe4RwlQNchNByi7wbcMAy6LNL5nWifAZ0Tz7RsvNs8G4Hfdu_I29pZ5Oyo0IZT_TGHtswOdNyZebFztiQIyv4jzVsT_HYabCYqpf-0VT5VSURUjxJEMdZPUO18mhGz9WBtEmM9gwKQxxcO4E_xl%3D)

---

### © 2022 The Institute for Research and Evaluation (IRE)

IRE is a nonprofit research agency that has been evaluating prevention programs for more than 30 years, specializing in sex education in schools—involving more than 100 evaluation studies and 900,000 teens, including studies in 30 U.S. states (many federally-funded) and three international countries. IRE has been an invited consultant on sex education effectiveness at the U.S. House of Representatives and Senate, The White House, and state legislatures. IRE research has been presented at the National Academies of Sciences (2019), the United Nations Civil Societies Conference (2019), and the U.S. Department of Health and Human Services (2020), and published in peer-reviewed journals, including *The American Journal of Preventive Medicine*, *The American Journal of Health Behavior*, and *Issues in Law and Medicine*.

**Contact:** Dr. Stan Weed at [weedstan@aol.com](mailto:weedstan@aol.com)

**This document is available at:** [https://institute-research.com/pdf/Transgender\\_Research--5\\_Questions\\_for\\_Parents\\_%26\\_Policymakers\\_%28IRE%2019-26-22%29.pdf](https://institute-research.com/pdf/Transgender_Research--5_Questions_for_Parents_%26_Policymakers_%28IRE%2019-26-22%29.pdf)

## **PROTECTING MINORS FROM THE HARMS OF PUBERTY BLOCKERS, CROSS-SEX HORMONES, AND IRREVERSIBLE SURGERIES**

State lawmakers have a duty to protect citizens' health and safety. This responsibility is even more significant when protecting vulnerable children.

Children who experience discomfort with their biological sex deserve to be treated with dignity and respect and need compassionate, effective mental health care. But radical activists and profit-driven gender clinics have deceived children and parents alike into believing that unnatural, life-altering and even permanently sterilizing puberty blockers, hormones, and surgeries are the solution to their struggle.

State lawmakers can protect children and parents from being pressured into agreeing to these harmful, experimental “gender transition” procedures by enacting laws that prohibit the administration of puberty blockers, cross-sex hormones, and surgeries on minors who experience discomfort with their biological sex.

We must be clear: the experimental gender-transition procedures—including puberty blocker and hormones—pushed on our children are often irreversible. They prevent healthy puberty, radically alter the child's hormonal balance, and may even remove healthy external or internal organs and body parts.

Such drugs and procedures are not only dangerous, but they are also experimental and unproven. In fact, multiple long-term studies show that when young children who experience gender dysphoria are allowed to mature naturally, most of them—over 90 percent according to some sources—grow out of their dysphoria.

And there is a growing movement of “detransitioners” who have come to realize—after undergoing puberty blockers, hormone treatments, and more—that they were lied to and that their medical gender transition was a devastating mistake. Many are now bravely speaking out about the damage caused by being rushed into these drugs and procedures without understanding the consequences.

But to fully protect vulnerable children from these harms, lawmakers cannot ignore that puberty blockers and cross-sex hormones—regularly pushed by gender clinics as part of the “gender affirmation” protocols—are just as damaging to children as the surgical procedures.

### **I. Puberty Blockers Have Not Been Shown to Be Safe or Reversible**

No study has ever demonstrated that the use of puberty blockers on children with gender dysphoria is safe. As a recent paper from Professor Michael Biggs of Oxford University explained, the claims that puberty blockers and other hormonal interventions are safe and reversible is “increasingly implausible.”

Rather, growing evidence shows that puberty blockers hurt a child's physical, emotional, and psychological development in ways that we still don't understand:

- **FDA Warnings:** In July 2022, the FDA issued a warning that puberty blockers carry a risk of pseudotumor cerebri, a disease with symptoms that include swelling of the optic nerve, headaches, vomiting, elevated blood pressure, and eye muscle paralysis.
- **Fertility Issues:** Puberty blockers prevent the natural development of a child's reproductive organs (i.e., ovaries and testes). Yet there has not been a single study on whether children will develop full reproductive capacity after the prolonged use of puberty blockers. As a result, the Endocrine Society has cautioned about this troubling lack of data on the long-term effects that blockers may have on child's fertility.
- **Impaired Brain Development:** Children experience vital neurological growth and development during puberty. But as the Endocrine Society warns, the use of puberty blockers on children "may include ... unknown effects on brain development." Researchers in the U.K. have expressed that:

A closely linked concern [arising from use of puberty blockers] is the unknown impacts on development, maturation and cognition if a child or young person is not exposed to the physical, psychological, physiological, neurochemical and sexual changes that accompany adolescent hormone surges.

- **Lower Bone Strength:** Numerous studies prove that puberty blockers diminish bone density. After just two years on puberty blockers, children's bone density levels were at dangerously low levels, with some children having spinal densities at the bottom 0.13% of the population.

## **II. Cross-Sex Hormones Have Not Been Shown to be Medically Safe for Minors**

Just like with puberty blockers, there are no reliable studies about the safety of the long-term use of cross-sex hormones on minors. But there are some things we do know:

- **Extended use of cross-sex hormones will sterilize a child.** As the Endocrine Society has explained, the high doses of estrogen given to adolescent males causes severe "testicular damage," while large doses of testosterone on young females impacts ovarian function. That led one research to warn that "cross-sex hormones ... may have irreversible effects."
- **Cross-sex hormones cause cardiovascular harm.** Three different studies have found that cross-sex hormones increase the occurrence of several cardiovascular diseases, strokes, blood clots, and other severe cardiovascular issues.

## **III. Puberty Blockers and Hormones Lead to Sterilizing and Irreversible Surgeries**

Putting a child experiencing gender dysphoria on puberty blockers is not a "pause button" as some gender activists claim. Instead, giving children puberty blockers and

hormones places them on a one-way street that virtually always leads them to sterilizing, irreversible surgeries.

For example, a recent study from the world's largest gender clinic in the United Kingdom found that 98% of children who were administered puberty blockers went on to eventually receive cross-sex hormones. This aligned with a similar study from the Netherlands that found that nearly 97% of children given puberty blockers proceeded to cross-sex hormones.

And when children received cross-sex hormones alone (or with puberty blockers), 100% of those children went on to receive damaging, irreversible surgeries according to three Dutch clinical studies. As explained by Dr. Stephen Levine:

These studies demonstrate that going on puberty blockers virtually eliminates the possibility of desistance in juveniles. Rather than a 'pause,' puberty blockers appear to act as a psychosocial 'switch,' decisively shifting many children to a persistent transgender identity. Therefore, as a practical and ethical matter the decision to put a child on puberty blockers must be considered as the equivalent of a decision to put that child on cross-sex hormones ...

This one-way street toward "transition" surgeries mutilates healthy bodies, turns children into lifelong customers of gender clinics, and irreparably deprives them of the fulfillment and basic human right of potentially becoming natural parents later in their lives, all with no proven long-term benefits. Worst of all, the surgeries lead to tragically higher rates of suicide. One study from Sweden showed that individuals who were subject to gender transition surgery had suicide rates almost 20 times higher than their peers.

#### **IV. Several Nations Are Restricting or Backing Away from Puberty Blockers and Cross-Sex Hormones for Minors**

A growing number of nations, including some that pioneered these medical transitions, are reversing course. Health authorities and medical associations in England, Sweden, Finland, France, Australia, and New Zealand are warning against, and even curtailing the use of puberty blockers, hormones, and surgeries on children with gender dysphoria:

- Sweden: The country's main gender clinic will no longer authorize puberty blockers and hormones to be given to minors under the age of 16 because "the risks of puberty suppressing treatment ... and gender-affirming hormonal treatment currently outweigh the possible benefits ... based on ... continued lack of reliable scientific evidence concerning the efficacy and the safety of both treatments."
- Finland: The country severely restricts the use of puberty blockers and hormones except for exceptional case after extensive psychiatric assessment of the child,

warning that “no decisions should be made that can permanently alter a still-maturing minor’s mental and physical development.”

- United Kingdom: Recently, the National Health Service eliminated their “gender clinic” model of care, suspended the use of puberty blockers and hormones except for purely research purposes, and instead announced that “psychological support” and “a watchful approach” are the recommend treatment for gender dysphoria.
- France: The National Academy of Medicine issued a statement urging “great medical caution” when working with children experiencing gender dysphoria “given the vulnerability, particularly psychological, of this population and the many undesirable effects, and even serious complications, that some of the available therapies can cause.”
- Australia & New Zealand: The Royal Australian and New Zealand College of Psychiatrists recently emphasized that treatments for gender dysphoria should focus on psychotherapy and address “co-existing issues which may need addressing and treating.”

In other words, these countries are putting psychological treatment and counseling at the forefront of caring for these children, who often suffer from other psychiatric conditions, not puberty blockers, hormones, or surgeries.

## CONCLUSION

Denying the truth that each and every person is either male or female hurts real people, especially vulnerable children. Science and common sense tell us that children are not mature enough to properly evaluate the serious, lifelong ramifications when making important medical decisions. And the decision to undergo dangerous, experimental, and likely sterilizing gender transition procedures is no exception.

States must enact laws that protect minors from adults who would push them toward life-altering, sterilizing treatments that cause permanent harm. Lawmakers must stand for the children they have a responsibility to protect.